Methods: Four BC PC patients, who had undergone cytoreductive surgery (CRS) + hyperthermic intraperitoneal chemotherapy (HIPEC), participated in this study. Clinicopathologic characteristics and overall survival (OS) data were collected and analyzed. Results: Patients' average age when they underwent CRS + HIPEC was 59.8 years. The average that hyperthermic intraperitoneal chemotherapy (HIPEC) can prolong the overall survival of patients with peritoneal carcinomatosis in a variety of malignant tumors, including GC (11,12). Mi et al. reported that compared with surgery alone, radical gastrectomy with prophylactic HIPEC in AGC patients could safely improve survival rates and cleusandDNAdamageanddisruptionofcellmembrane [10]. Inaddition, itwasfurtherdemonstratedthattumor cellsaremoresensitivetohyperthermiawithrespecttonor- The PDF file you selected should load here if your Web browser has a PDF reader plug-in installed (for example, a recent version of Adobe Acrobat Reader). Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes. Article Options. plus hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with the peritoneal metastasis of epithelial ovarian cancer (EOCPC). Methods: In patients with ovarian cancer who underwent surgery-based multidisciplinary treatment at our center from May 2004 to November 2019, 186 EOCPC patients were divided into a control group